Medtronic has that announced Jeffrey J Popma (Harvard Medical School; Beth Israel Deaconess Medical Center, Boston, USA) will join the company as vice president and chief medical officer supporting the coronary, renal denervation, and structural heart businesses. A press release reports that Popma will serve as a strategic adviser for cardiovascular device innovation, and assist in the development of an expanding clinical research portfolio, leveraging his deep expertise in interventional cardiology and transcatheter-based therapies.
The press adds release that he will officially assume this role on 22 June 2020 and report to Nina Goodheart, president of the Coronary & Structural Heart (CSH) division, which is part of the Cardiac and Vascular Group.
Popma is an internationally renowned interventional cardiologist, who is an expert in transcatheter aortic valve replacement and transcatheter mitral and tricuspid valve therapies. He is past president of the Society of Cardiac Angiography and Interventions (SCAI) and served as chairman of the American College of Cardiology (ACC) Cardiac Catheterization Committee.
Furthermore, he has directed numerous multicentre cardiovascular device clinical trials. Over the past 20 years these clinical trials have included a broad array of new technology, including aortic valve prostheses, bare metal stents, drug-eluting stents, distal protection devices, total occlusion devices, and carotid and peripheral revascularisation procedures.
Nina Goodheart, president, Coronary & Structural Heart, Medtronic, says: “We could not be more excited to welcome Dr Popma to Medtronic. Dr Popma is a world-renowned clinical researcher and thought leader within the interventional cardiology space, and a long-time advisor and study investigator for Medtronic. We are honoured that Jeff will bring his clinical, medical and scientific knowledge and expertise to CSH to help us further the Medtronic Mission.”
Popma comments: “I am honoured to be joining Medtronic to help deliver on its enduring Mission of patient-focused medical device innovation. I look forward to collaborating with the talented cardiovascular and structural heart teams at Medtronic and listening to the guidance of their clinical advisors to help develop product solutions and clinical evidence strategies for the betterment of patients. I am also incredibly appreciative of the exceptional physicians and dedicated nurses who have supported me during my tenure at Beth Israel Deaconess Medical Center. I look forward to ongoing collaboration with these inspirational colleagues in the future.”
